Combination therapy with pulse cyclophosphamide plus corticosteroids improves renal outcome in patients with lupus nephritis

Rezaie-Yazdi, Z. and Forghanizadeh, J. and Rezaie, J. and Salehian, P. and Torghabeh, H.M. (2005) Combination therapy with pulse cyclophosphamide plus corticosteroids improves renal outcome in patients with lupus nephritis. Medical Journal of the Islamic Republic of Iran, 19 (2). pp. 109-117.

[img] Text
admin-A-10-1-273-a9fd145.pdf

Download (2MB)
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: The prognosis of SLE is influenced by the onset of glomerulonephritis. Clinical trials in lupus nephritis have demonstrated that cyclophosphamide therapy is the superior regimen in the management of lupus nephritis for preserving renal function. Objective: The purpose of this study is to define the outcome of renal function with bolus pulses of cyclophosphamide and steroid according to our protocol and also to determine an appropriate pattern of treatment of lupus nephritis. Methods: In this open-label clinical trial, to evaluate the results, the short-term prognosis and the rate of complications of an immunosuppressive regimen with corticosteroids and cyclophosphamide, twenty-five patients with biopsy-proven lupus nephritis were studied. Treatment was structured in 4 phases: 1) Induction with bolus methylprednisolone and cyclophosphamide. 2) Maintenance with oral prednisolone for 4 weeks and monthly cyclophosphamide pulses for 6 months. 3) Tapering with reduction of prednisolone by 10 each month and continuing cyclophosphamide every other month till one year and for the second year every 3 months. 4) Discontinuation with oral prednisolone slowly tapered to the least effective daily dose and cyclophosphamide discontinued after 2 yr of therapy. We defined primary outcome measures according to these criteria: renal function return to normal limits or become stable, regression of systemic and local inflammatory symptoms, urine protein excretion falling below 0.3 gr/dL or by at least 50, RBC cast disappearance, C3, C4, Hb, and ESR return to normal limits. Results: Twenty-three patients with lupus nephritis completed our therapeutic protocol. Renal biopsy was performed in 22 cases and indicated type IV in 20 patients (95.2), and type V in 2 patients. After an average of 4+1.95 months 22 patients achieved remission (95.65) and only one case remained non-responsive. She became pregnant in her fourth month of therapy. Significant statistical differences were achieved between creatinine, proteinuria, hematuria, leukocyturia, urinary cast, C3, C4, ESR, and Hb before and after therapy (p<0.05). Plasma creatinine fell from 1.44+0.95 mg/dL to 0.97+0.78 (p<0.004). Proteinuria fell from 1879.78+1854.46 to 408.34+572.92 mg/24h (p<0.001). Thirteen episode of relapses were treated again with repeated cycles of cyclophosphamide and all remitted again. Conclusion: Intensive immunosuppression with steroid and cyclophosphamide provides excellent results with an acceptable rate of complications in the treatment of lupus nephritis.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: cyclophosphamide; cyclosporin; hemoglobin; methylprednisolone; mycophenolic acid; mycophenolic acid 2 morpholinoethyl ester; prednisolone, add on therapy; article; clinical article; clinical trial; combination chemotherapy; controlled clinical trial; controlled study; drug dose reduction; drug dose regimen; drug efficacy; drug withdrawal; erythrocyte; glomerulonephritis; human; immunosuppressive treatment; infection; kidney biopsy; kidney function; lupus erythematosus nephritis; maintenance therapy; outcome assessment; prognosis; protein secretion; protein urine level; proteinuria; relapse; remission; treatment duration; treatment outcome; treatment response; world health organization
Subjects: WJ Urogenital System
Depositing User: Librarian Farzaneh Dini
Date Deposited: 12 May 2019 09:38
Last Modified: 12 May 2019 09:38
URI: http://eprints.iums.ac.ir/id/eprint/12218

Actions (login required)

View Item View Item